This synthetic vulnerability of cancer cells, particularly those already experiencing high levels of RS or defective DDR pathways, underpins the therapeutic rationale for ATR inhibitor monotherapy or combination regimens that further destabilize replication processes. The gene discussed is ATR; the disease is cancer.